Health
Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors – FierceBiotech
Activating the immune pathway STING creates an inflammatory environment that should improve immuno-oncology treatments, but clinical trials have been disappointing…
The immune pathway known as stimulator of interferon genes (STING) has long been of interest in the oncology community because activating it creates an inflammatory environment that should improve the ability of immune cells to attack cancer. But experimental STING-activating treatments have produced mixed results in clinical trials.
Researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center have promising evidence that adding STING activators to CAR-T cell therapies…
-
General17 hours agoAmbulance response times sluggish despite Tasmanian ramping ‘ban’ promise
-
General22 hours agoEnergy chiefs say net zero ‘irreversible’ even though bills unlikely to fall ‘for a decade’
-
Business13 hours agoWhat it means for shareholders
-
Noosa News14 hours agoBrisbane’s new bus timetable sees journey times decrease by two minutes in first three months